|
Virtual Meetings 2023
Meet The Professor: Optimizing the Management of Multiple MyelomaFor an up-to-date schedule of upcoming sessions in this series, please click here. PARTICIPATING FACULTY
Shaji K Kumar, MD Mark and Judy Mullins Professor of Hematological Malignancies Consultant, Division of Hematology Professor of Medicine Mayo Clinic Rochester, Minnesota Sagar Lonial, MD Chair and Professor Department of Hematology and Medical Oncology Anne and Bernard Gray Family Chair in Cancer Chief Medical Officer Winship Cancer Institute Emory University School of Medicine Atlanta, Georgia Noopur Raje, MD Director, Center for Multiple Myeloma Massachusetts General Hospital Cancer Center Professor of Medicine Harvard Medical School Boston, Massachusetts Paul G Richardson, MD Clinical Program Leader and Director of Clinical Research Jerome Lipper Multiple Myeloma Center Dana-Farber Cancer Institute RJ Corman Professor of Medicine Harvard Medical School Boston, Massachusetts SERIES MODERATOR Neil Love, MD Research To Practice These activities are supported by educational grants from AbbVie Inc, GlaxoSmithKline, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Karyopharm Therapeutics. Agenda
MODULE 1: Optimizing the Selection of First-Line Therapy for Patients with Multiple Myeloma MODULE 2: Integration of Novel Therapies into the Treatment of Relapsed/Refractory Disease MODULE 3: Incorporation of CAR (Chimeric Antigen Receptor) T-Cell Therapy into the Care of Patients with Multiple Myeloma MODULE 4: Novel Investigational Agents for Multiple Myeloma
Target Audience
CE Credit American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC) Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of each activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. FACULTY — The following faculty reported relevant financial relationships with ineligible entities: Dr Kumar — Advisory Committee: AbbVie Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc; Consulting Agreements (No Personal Payments): AbbVie Inc, Amgen Inc, Arcellx, AstraZeneca Pharmaceuticals LP, bluebird bio, Bristol-Myers Squibb Company, Epizyme Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, K36 Therapeutics, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Monte Rosa Therapeutics, Sanofi, Secura Bio, Takeda Pharmaceuticals USA Inc, Trillium Therapeutics Inc; Consulting Agreements (with Personal Payments): Antengene, BeiGene Ltd, Oncopeptides; Data and Safety Monitoring Board/Committee: Bristol-Myers Squibb Company, Janssen Biotech Inc; Research Funding for Clinical Trials to the Institution: AbbVie Inc, Allogene Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, CARsgen Therapeutics, Genentech, a member of the Roche Group, GlaxoSmithKline, Janssen Biotech Inc, Novartis, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc. Dr Lonial — Advisory Committee: AbbVie Inc, Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, a member of the Roche Group, GlaxoSmithKline, Janssen Biotech Inc, Novartis, Pfizer Inc, Takeda Pharmaceuticals USA Inc; Board of Directors with Stock: TG Therapeutics Inc; Contracted Research: Bristol-Myers Squibb Company, Janssen Biotech Inc, Novartis, Takeda Pharmaceuticals USA Inc. Dr Raje — Advisory Committee: bluebird bio, Bristol-Myers Squibb Company, Caribou Biosciences Inc, Celgene Corporation, Immuneel Therapeutics, Janssen Biotech Inc, Merck, Novartis, Onyx Pharmaceuticals, an Amgen subsidiary, Takeda Pharmaceuticals USA Inc; Contracted Research: bluebird bio; Steering Committee: Amgen Inc, Roche Laboratories Inc. Dr Richardson — Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, Karyopharm Therapeutics, Oncopeptides, Sanofi, Secura Bio, Takeda Pharmaceuticals USA Inc; Contracted Research: Bristol-Myers Squibb Company, Celgene Corporation, Karyopharm Therapeutics, Oncopeptides, Takeda Pharmaceuticals USA Inc.SURVEY PARTICIPANTS — Rafael Fonseca, MD — Consulting Agreements: AbbVie Inc, Amgen Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline, H3 Biomedicine, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Karyopharm Therapeutics, Kite, A Gilead Company, Merck, Novartis, Oncopeptides, ONCOtracker, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Regeneron Pharmaceuticals Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Scientific Advisory Board: Adaptive Biotechnologies Corporation, Caris Life Sciences, OncoMyx Therapeutics, ONCOtracker. Ola Landgren, MD, PhD — Advisory Committee: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, GlaxoSmithKline, Karyopharm Therapeutics, Pfizer Inc, Sanofi; Consulting Agreements: Adaptive Biotechnologies Corporation, Regeneron Pharmaceuticals Inc; Contracted Research: Amgen Inc, Celgene Corporation, Janssen Biotech Inc, Takeda Pharmaceuticals USA Inc; Data and Safety Monitoring Board/Committee: Janssen Biotech Inc, Merck, Takeda Pharmaceuticals USA Inc. Joseph Mikhael, MD, MEd — Consulting Agreements: AbbVie Inc, Amgen Inc, Bristol-Myers Squibb Company, Janssen Biotech Inc, Karyopharm Therapeutics, Pfizer Inc, Sanofi, Takeda Pharmaceuticals USA Inc. SERIES MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc. RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.Supporters These activities are supported by educational grants from AbbVie Inc, GlaxoSmithKline, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Karyopharm Therapeutics. |